Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
30.07
+0.76 (2.59%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Revenue
In the year 2023, Supernus Pharmaceuticals had annual revenue of $607.52M, a decrease of -8.95%. Revenue in the quarter ending December 31, 2023 was $164.31M, a -1.80% decrease year-over-year.
Revenue (ttm)
$607.52M
Revenue Growth
-8.95%
P/S Ratio
2.71
Revenue / Employee
$931,781
Employees
652
Market Cap
1.65B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
Dec 31, 2018 | 408.90M | 106.66M | 35.29% |
Dec 31, 2017 | 302.24M | 87.24M | 40.57% |
Dec 31, 2016 | 215.00M | 67.54M | 45.80% |
Dec 31, 2015 | 147.47M | 54.79M | 59.12% |
Dec 31, 2014 | 92.68M | 80.66M | 671.10% |
Dec 31, 2013 | 12.02M | 10.54M | 712.09% |
Dec 31, 2012 | 1.48M | 677.00K | 84.31% |
Dec 31, 2011 | 803.00K | 697.00K | 657.55% |
Dec 31, 2010 | 106.00K | -37.82M | -99.72% |
Dec 31, 2009 | 37.93M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Myriad Genetics | 753.20M |
Warby Parker | 669.77M |
Taro Pharmaceutical Industries | 610.83M |
U.S. Physical Therapy | 604.80M |
Harmony Biosciences Holdings | 582.02M |
UFP Technologies | 400.07M |
Zai Lab | 266.72M |
Ginkgo Bioworks Holdings | 251.46M |
SUPN News
- 3 days ago - Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - GlobeNewsWire
- 7 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN - PRNewsWire
- 19 days ago - Supernus Provides Regulatory Update for SPN-830 - GlobeNewsWire
- 7 weeks ago - Supernus to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 - GlobeNewsWire
- 2 months ago - Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent - GlobeNewsWire